After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to ...

The program will allow for frequent communication with the FDA, giving manufacturers timely input and guidance regarding the ...

While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

While CagriSema bested Novo Nordisk's Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma's 25% weight loss goal.

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.

Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.

AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.

A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data ...

With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...